 |
BeneVir Biopharm
Matthew Mulvey, CEO & Co-founder
USA | Funding: $7M (+)
Website: http://benevir.com/
The BeneVir oncolytic virus platform is based on T-StealthTM technology, which overcomes a major barrier to the clinical success of oncolytic viruses. This barrier is the body’s immune system, which is very effective at killing both harmful viruses (like flu) and beneficial viruses (like oncolytic viruses).
Website: http://benevir.com/
The BeneVir oncolytic virus platform is based on T-StealthTM technology, which overcomes a major barrier to the clinical success of oncolytic viruses. This barrier is the body’s immune system, which is very effective at killing both harmful viruses (like flu) and beneficial viruses (like oncolytic viruses).
